15.05.2024  11:03:15 Zm. +3,00 Wolumen Bid11:04:34 Ask11:04:34 Kapitalizacja Rynkowa St. dywidendy Wskaźnik C/Z
248,20CHF +1,22% 3 728
Obrót: 921 850,10
248,00Wolumen Bid: 108 248,40Wolumen Ask: 250 210,45 mldCHF 3,82% 17,25

Opis działalności

Headquartered in Basel, Switzerland, Roche is a leader in research-focused healthcare with combined strengths in pharmaceuticals and diagnostics. Roche is the world’s largest biotech company, with truly differentiated medicines in oncology, immunology, infectious diseases, ophthalmology and neuroscience. Roche is also the world leader in in vitro diagnostics and tissue-based cancer diagnostics, and a frontrunner in diabetes management. Roche’s personalised healthcare strategy aims at providing medicines and diagnostics that enable tangible improvements in the health, quality of life and survival of patients. Founded in 1896, Roche has been making important contributions to global health for more than a century. Twenty-four medicines developed by Roche are included in the World Health Organisation Model Lists of Essential Medicines, among them life-saving antibiotics, antimalarials and chemotherapy.
 

Zarząd & Rada nadzorcza

CEO
Dr. Thomas Schinecker
Zarząd
Dr. Alan Hippe, Cristina A. Wilbur, Teresa Graham, Matt Sause , Claudia Bockstiegel, Prof. Dr. Hans Clevers, Dr. Levi Garraway, Silke Hornstein, Dr. Aviv Regev, Dr. James H. Sabry, Barbara Schadler
Rada nadzorcza
André Hoffmann, Anita Hauser, Bernard Poussot, Dr. Claudia Süssmuth Dyckerhoff, Dr. Patrick Frost, Dr. Severin Schwan, Prof. Dr. Richard Lifton, Dr. Mark Schneider, Dr. Jemilah Mahmood, Prof. Dr. Akiko Iwasaki, Dr. Joorg Duschmale
 

Dane firmy

Nazwa: Roche Holding
Adres: Grenzacherstraße 124,CH-4070 Basel
Telefon: +41-61-688-1111
Fax: -
E-mail: basel.webmaster@roche.com
Internet: www.roche.com
Przemysł: Służba zdrowia
Sektor: Przemysł Farmaceutyczny
Podsektor: Przemysł Farmaceutyczny
Koniec roku finansowego: 31.12
Free float: 88,00%
Data IPO: 03.04.1995

Relacje inwestorskie

Nazwa: Bruno Eschli
Telefon: +41 (61) 687 5284
Fax: +41 (61) 691 0014
E-mail: investor.relations@roche.com

Główni akcjonariusze

Aktionärsgruppe der Familien Hoffmann und Oeri-Hoffmann
 
67,50%
Freefloat
 
24,92%
Maja Oeri
 
7,58%